Program
tulmimetostat
Also written as “Tulmimetostat”, “Tulmimetostat DL1 QD” and “Tulmimetostat DL2 QD”.
In Novartis's pipeline, EZH1, EZH2 inhibitor
. Its studies are mostly in Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms · Lymphoma, Large B-Cell, Diffuse, led by Novartis.
Furthest: phase 2, since Sep 23, 20193 company-led studies, 3 open or runningNext primary completion: Nov 9, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 33 open or running | phase 2since Sep 23, 2019 | Sep 23, 2019 | Nov 9, 2029phase 2 · NCT07206056 |
- Named in Novartis’s own pipeline as
DZR123 (tulmimetostat)
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 23, 2019First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT04104776 · 300 planned · United States, France, Italy and more
- Sep 16, 20252 phase 2 studiesNCT07190300, NCT07206056
Ahead
- Nov 9, 2029Primary completion: phase 2 study in Progressive Metastatic Castrate Resistant Prostate CancerNCT07206056
- Feb 27, 2030Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04104776
- Aug 2, 2032Primary completion: phase 2 study in Bulbo-Spinal Atrophy, X-LinkedNCT07190300
TargetBeta
“EZH1, EZH2 inhibitor”the company's pipeline, read by Claude · source
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 2 |
| valemetostatrule | Daiichi Sankyo | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer · United States, Australia, Canada and more | 2 | Recruiting | Nov 9, 2029 | 188 |
| NCT07190300Bulbo-Spinal Atrophy, X-Linked · United States, Australia, Brazil and more | 2 | Recruiting | Aug 2, 2032 | 181 |
| NCT04104776Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more | 2 | Recruiting | Feb 27, 2030 | 300 |
How it is read
Names in the registry
- “Tulmimetostat”, 2 entries
- “Tulmimetostat DL1 QD”, 1 entry
- “Tulmimetostat DL2 QD”, 1 entry
- “Tulmimetostat DL3 QD”, 1 entry
- “Tulmimetostat Doses 1 or 2 QD”, 1 entry
Conditions, from the studies’ own filings
- Bulbo-Spinal Atrophy, X-Linked, 1 study
- Prostatic Neoplasms, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.